GlaxoSmithKline and ChemoCentryx today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN (CCX282-B), a specific CCR9 antagonist that could offer a new approach for treating inflammatory bowel diseases. The option also encompasses two further identified backup compounds and represents the first product licensing opportunity resulting from the original collaboration with ChemoCentryx through GSK's Center of Excellence for External Drug Discovery. Release